Market Overview

UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Celgene Corporation

Share:
Related CELG
Amgen, Celgene Buck Short Interest Trend In Biotech Stocks
Icahn, Gilead, GE Lead Top Insider Trades Of The Week
The Gilead Sell-Off: An Opportunity Of A Lifetime (Seeking Alpha)

In a report published Friday, Jefferies reiterated its Buy rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $104.00 to $114.00.

Jefferies noted, “On its 4Q earnings call, CELG focused details around achieving the 2017 guidance laid out earlier this month. We are raising our price target from $104 to $114 as we are adding modest apremilast to our valuation and raising our expectations for Abraxane penetration in pancreatic cancer following positive Phase 3 data released yesterday.”

Celgene Corporation closed on Thursday at $97.49.

Latest Ratings for CELG

DateFirmActionFromTo
Feb 2016Leerink SwannInitiates Coverage onMarket Perform
Jan 2016Credit SuisseMaintainsOutperform
Jan 2016Credit SuisseInitiates Coverage onOutperform

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (CELG)

Get Benzinga's Newsletters